Article PDF
Avoid common mistakes on your manuscript.
References
Zhang JJ, Chen H, He K, et al. Evaluation of blinded independent central review of tumor progression in oncology clinical trials: a meta-analysis. Therapeutic Innovation & Regulatory Science. 2013;47(2):167–174.
Amit O, Mannino F, Stone A, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer. 2011;47(12):1772–1778.
Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–1260.
FDA. FDA Briefing Document Oncologic Drugs Advisory Committee Meeting. April 12, 2011. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeeting-Materials/Drugs/OncologicDrugsAdvisoryCommittee/ucm250378.pdf. Accessed June 25, 2013.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Raunig, D., Goldmacher, G. & Conklin, J. Local Evaluation and Blinded Central Review Comparison: A Victim of Meta-Analysis Shortcomings. Ther Innov Regul Sci 47, NP1–NP2 (2013). https://doi.org/10.1177/2168479013499572
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479013499572